[go: up one dir, main page]

WO2003062385A3 - Secretory molecules - Google Patents

Secretory molecules Download PDF

Info

Publication number
WO2003062385A3
WO2003062385A3 PCT/US2003/001605 US0301605W WO03062385A3 WO 2003062385 A3 WO2003062385 A3 WO 2003062385A3 US 0301605 W US0301605 W US 0301605W WO 03062385 A3 WO03062385 A3 WO 03062385A3
Authority
WO
WIPO (PCT)
Prior art keywords
sptm
provides
diagnostic assays
purified
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001605
Other languages
French (fr)
Other versions
WO2003062385A2 (en
Inventor
Anissa L Jones
Christopher R Dahl
Darryl Gietzen
Joyce Chinn
Gerard E Dufour
Jennifer L Jackson
Jimmy Y Yu
Olivia Tuason
Pierre E Yap
Stefan R Amshey
Tam C Dam
Tommy F Liu
Edward H Gerstin Jr
Careyna H Peralta
Samantha A Lewis
Alice J Chen
Rakesh Marwaha
Ruth Y Lan
Michael E Urashka
Sreenivasa R Kristnam
Vijaykumar Kolluru
Iqbal S Panesar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to AU2003236612A priority Critical patent/AU2003236612A1/en
Publication of WO2003062385A2 publication Critical patent/WO2003062385A2/en
Anticipated expiration legal-status Critical
Publication of WO2003062385A3 publication Critical patent/WO2003062385A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides purified secretory polynucleotides (sptm). Also encompassed are the polypeptides (SPTM) encoded by sptm. The invention also provides for the use of sptm, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing sptm for the expression of SPTM. The invention additionally provides for the use of isolated and purified SPTM to induce antibodies and to screen libraries of compounds and the use of anti-SPTM antibodies in diagnostic assays. Also provided are microarrays containing sptm and methods of use.
PCT/US2003/001605 2002-01-17 2003-01-15 Secretory molecules Ceased WO2003062385A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003236612A AU2003236612A1 (en) 2002-01-17 2003-01-15 Secretory molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34941302P 2002-01-17 2002-01-17
US34994602P 2002-01-17 2002-01-17
US60/349,946 2002-01-17
US60/349,413 2002-01-17

Publications (2)

Publication Number Publication Date
WO2003062385A2 WO2003062385A2 (en) 2003-07-31
WO2003062385A3 true WO2003062385A3 (en) 2006-09-08

Family

ID=27616740

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/001363 Ceased WO2003062379A2 (en) 2002-01-17 2003-01-14 Molecules for disease detection and treatment
PCT/US2003/001605 Ceased WO2003062385A2 (en) 2002-01-17 2003-01-15 Secretory molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001363 Ceased WO2003062379A2 (en) 2002-01-17 2003-01-14 Molecules for disease detection and treatment

Country Status (2)

Country Link
AU (2) AU2003205174A1 (en)
WO (2) WO2003062379A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641922B1 (en) * 2003-07-07 2012-09-26 Universiteit Utrecht Holding B.V. Newly identified cholinephosphotransferases and ethanolaminephosphotransferases
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 substituted nucleotide analogs
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993827A (en) * 1993-09-10 1999-11-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
US6277977B1 (en) * 1997-06-11 2001-08-21 Smithkline Beecham Corporation cDNA clone HAPOI67 that encodes a human 7-transmembrane receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993827A (en) * 1993-09-10 1999-11-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
US6277977B1 (en) * 1997-06-11 2001-08-21 Smithkline Beecham Corporation cDNA clone HAPOI67 that encodes a human 7-transmembrane receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Also Published As

Publication number Publication date
WO2003062385A2 (en) 2003-07-31
AU2003236612A8 (en) 2006-11-09
WO2003062379A2 (en) 2003-07-31
WO2003062379A3 (en) 2004-02-19
AU2003205174A1 (en) 2003-09-02
AU2003236612A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2004023973A3 (en) Molecules for diagnostics and therapeutics
WO2002097031A3 (en) Molecules for diagnostics and therapeutics
WO2002083876A3 (en) Secretory molecules
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2004092209A3 (en) S. pneumoniae antigens
WO2004078907A3 (en) Streptococcus pyogenes antigens
WO2001004264A3 (en) Atherosclerosis-associated genes
WO2005103073A3 (en) Td antigens
AU2003224674A1 (en) Compounds and methods for analyzing the proteome
WO2003020894A3 (en) Insulin related transcription factor and uses thereof
WO2002046228A3 (en) Receptor for b. anthracis toxin
WO2002099080A3 (en) Methods for low background cloning of dna using long oligonucleotides
WO2002020756A3 (en) Secretory molecules
WO2003062376A3 (en) Molecules for diagnostics and therapeutics
WO2002040715A8 (en) Molecules for disease detection and treatment
WO2003062385A3 (en) Secretory molecules
WO2004106367A3 (en) Enterococcus antigens
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2004094467A3 (en) H. pylori antigens
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
WO2001062922A3 (en) Polypeptides and corresponding molecules for disease detection and treatment
WO2002055738A3 (en) Molecules for disease detection and treatment
WO2002057304A3 (en) Secretory molecules
WO2002020754A3 (en) Molecules for diagnostics and therapeutics
WO2003008626A3 (en) Novel human nucleic acids encoding a pantothenate kinase and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP